Therapeutic benefits of putrescine-modified catalase in a transgenic mouse model of familial amyotrophic lateral sclerosis

Experimental Neurology

Volumn 159, Issue 1, 1999, Pages 204-216

  Reinholz, Monica M ^a   Merkle, Carolin M ^a   Poduslo, Joseph F ^a  

^a MAYO CLINIC   (United States)

Author keywords

Amyotrophic lateral sclerosis (ALS); Antioxidant; Blood brain barrier; Free radical; Neurodegeneration; Transgenic

Indexed keywords

ALANINE; CATALASE; COPPER ZINC SUPEROXIDE DISMUTASE; GLYCINE; PEROXIDASE; PUTRESCINE;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME MODIFICATION; GENE MUTATION; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MOTOR NEURON DISEASE; MOUSE; NONHUMAN; ONSET AGE; OXIDATIVE STRESS; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; SURVIVAL TIME; TRANSGENIC MOUSE;

EID: 0032827346     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.1999.7142     Document Type: Article

References (92)

1. Abe K., Pan L-H., Watanabe H. Upregulation of protein-tyrosine nitration in the anterior horn cells of amyotrophic lateral sclerosis. Neurol. Res. 19:1997;124-1271.
2. Acworth I. N., Phil D., Bailey B. The Handbook of Oxidative Metabolism, 2.1-2.5, 3.1-3.2, 4.1-4.7, 5.1-5.13. 1995;ESA Inc. Chemsford.
3. Adams D. H., Burgess E. H. The effect of the degree of homogenization on the catalase activity of liver "homogenates." Br. J. Cancer. 11:1957;310-325.
4. Ausbel F. M. Standard procedures and optimization. Curr. Protocol. Mol. Biol. 2:1997;15.1.1-15.1.5.
5. Beal M. F., Ferrante R. J., Browne S. E. Increased 3-nitrotyrosine in both sporadic and familial amyotrophic lateral sclerosis. Ann. Neurol. 42:1997;644-654.
6. Beckman J. S., Beckman T. W., Chen J. Apparent hydroxyl radical production by peroxynitrite: Implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. USA. 87:1990;1620-1624.
7. Beckman J. S., Carson M., Smith C. D., Koppenol W. ALS, SOD and peroxynitrite. Nature. 364:1993;584.
8. Beckman J. S., Ischiropoulos H., Zhu L. Kinetics of superoxide dismutase- and iron-catalyzed nitration of phenolics by peroxynitrite. Arch. Biochem. Biophys. 298:1992;438-445.
9. Benison G., Lacomblez L., Meininger V. A controlled study trial of riluzole in amyotrophic lateral sclerosis. N. Engl. J. Med. 330:1994;585-591.
10. Bruijn L. I., Beal M. F., Becher M. W. Elevated free nitrotyrosine levels, but not protein-bound nitrotyrosine or hydroxyl radicals, throughout amyotrophic lateral sclerosis (ALS)-like disease implicate tyrosine nitration as an aberrant in vivo property of one familial ALS-linked superoxide dismutase 1 mutant. Proc. Natl. Acad. Sci. USA. 94:1997;7606-7611.
11. Brown R. H. Amyotrophic lateral sclerosis: Recent insights from genetics and transgenic mice. Cell. 80:1995;687-692.
12. Brown R. H. Superoxide dismutase in familial amyotrophic lateral sclerosis: Models for gain of function. Curr. Opin. Neurobiol. 5:1995;841-846.
13. Chance B., Herbert D. The enzyme-substrate compounds of bacterial catalase and peroxides. Biochem. J. 46:1950;402-414.
14. Chance B., Maehly A. C. Assay of catalases and peroxidases. Methods Enzymol. 2:1955;764-791.
15. Chiu A. Y., Zhai P., Dal Canto M. C. Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol. Cell. Neurosci. 6:1995;349-362.
16. Cohen G., Dembiec D., Marcus J. Measurement of catalase activity in tissue extracts. Anal. Biochem. 34:1970;30-38.
17. Coyle J. T., Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 262:1993;689-695.
18. Crow J. P., Sampson J. B., Zhuang Y. Decreased zinc affinity of amyotrophic lateral sclerosis associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J. Neurochem. 69:1997;1936-1944.
19. Crow J. P., Ye Y. Z., Strong M. Superoxide dismutase catalyzes nitration of tyrosines by peroxynitrite in the rod and head domains of neurofilament-L. J. Neurochem. 69:1997;1945-1953.
20. Dal Canto M. C. Comparison of pathological alterations in ALS and a murine transgenic model: Pathogenetic implications. Clin. Neurosci. 3:1996;332-337.
21. Dal Canto M. C., Gurney M. E. A low expressor line of transgenic mice carrying a mutant human Cu,Zn superoxide dismutase (SOD1) gene develops pathological changes that most closely resemble those in human amyotrophic lateral sclerosis. Acta Neuropathol. 93:1997;537-550.
22. Dal Cantro M. C., Gurney M. E. Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice over-expressing wild type human SOD: A model of familial amyotrophic lateral sclerosis (FALS). Brain Res. 676:1995;25-40.
23. Deng H-X., Hentati A., Tainer J. A. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 261:1993;1047-1051.
24. Dugan L. L., Turetsky D. M., Du C. Carboxyfullereness as neuroprotective agents. Proc. Natl. Acad. Sci. USA. 94:1997;9434-9439.
25. Emery A. E. H., Holloway S. Familial motor neuron diseases. Rowland L. P. Human Motor Neuron Diseases. 1982;139-147 Raven Press, New York.
26. Epstein C. J., Chan P-H, Cadet J. L. Cu,Zn-superoxide dismutase transgenic mice in the study of the role of oxidative stress in neurodegenerative disorders. Neurodegenerative Disease. 1994;239-252.
27. Ferrante R. J., Browne S. E., Shinobu L. A. Evidence for increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J. Neurochem. 69:1997;2064-2074.
28. Gurney M. E. The use of transgenic mouse models of amyotrophic lateral sclerosis in preclinical drug studies. J. Neurol. Sci. 152:1997;S67-S73.
29. Gurney M. E. Transgenic animal models of familial amyotrophic lateral sclerosis. J. Neurol. 244:1997;S15-S20.
30. Gurney M. E., Cutting F. B., Zhai P. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39:1996;147-157.
31. Gurney M. E., Cutting F. B., Zhai P. Pathogenic mechanisms in familial amyotrophic lateral sclerosis due to mutation of Cu, Zn superoxide dismutase. Pathol. Biol. 44:1996;51-56.
32. Gurney M. E., Pu H., Chiu A. Y. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science. 264:1994;1772-1775.
33. Gardner D. J., Davis J. A., Weina P. J., Theune B. Comparison of tribromoethanol, ketamine/aetylpromazine, Telazol/xylazine, pentobarbital, and methoxyflurane anesthesia in HSD: ICR mice. Lab. Animal Sci. 45:1995;199-204.
34. Hall E. D., Andrus P. K., Fleck T. J., Gurney M. E., Roostveen J. A. Relationship of oxygen radical-induced lipid peroxidative damage to disease onset and progression in a transgenic model of familial ALS. J. Neurosci. Res. 53:1998;66-77.
35. Hottinger A. F., Fine E. G., Gurney M. E., Zurn A. D., Aebischer P. The copper chelator d-Penicillamine delays onset of disease and extends survival in a transgenic mouse model of familial amyotrophic lateral sclerosis. Eur. J. Neurosci. 9:1997;1548-1551.
36. Huie R. E., Padmaja S. The reaction of NO with superoxide. Free Radical Res. Commun. 18:1993;195-199.
37. Ince P. G., Shaw P. J., Candy J. M. Iron, selenium, and glutathione peroxidase activity are elevated in sporadic motor neuron disease. Neurosci. Lett. 82:1994;87-90.
38. Johansson L. H., Burg L. A. Spectrophotometric method for determination of catalase activity in small tissue samples. Anal. Biochem. 174:1988;331-336.
39. Jolly S. R., Kane W. J., Bailie M. B. Canine myocardial reperfusion injury: Its reduction by the combined administration of superoxide dismutase and catalase. Circ. Res. 54:1984;277-285.
40. Jones C. T., Brock D. J. H., Warlow C. P., Swingler R. J. Cu/Zn superoxide dismutase (SOD1) mutations and sporadic amyotrophic lateral sclerosis. Lancet. 342:1993;1050-1051.
41. Julka D., Pal R., Gill K. D. Neurotoxicity of dichlorvos: Effect on antioxidant defense system in the rat central nervous system. Exp. Mol. Pathol. 56:1992;144-152.
42. Kane D. J., Sarafian T. A., Anton R. Bcl-2 inhibition of neural death: Decreased generation of reactive oxygen species. Science. 262:1993;1274-1277.
43. Kim S. M., Kang J. H. Peroxidative activity of human Cu, Zn-superoxide dismutase. Mol. Cells. 7:1997;120-124.
44. Kostic V., Jackson-Lewis V., Bilbao F. Bcl-2: Prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science. 277:1997;559-562.
45. Lacomblez L., Bensimon G., Leigh P. N. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Lancet. 347:1996;1425-1431.
46. Liochev L. L., Chen R. A., Hallewell, Fridovich I. Superoxide-dependent peroxidase activity of H48Q: Oxide dismutase variant associated with amyotrophic lateral sclerosis. Arch. Biochem. Biophys. 346:1997;263-268.
47. Liu D. The roles of free radicals in amyotrophic lateral sclerosis. J. Mol. Neurosci. 7:1996;159-167.
48. Liu T. H., Beckman J. S., Freeman B. A. Polyethylene glycol-conjugated superoxide dismutase and catalase reduce ischemic brain injury. Am. J. Physiol. 256:1989;H589-H593.
49. Louvel E., Hugon J., Doble A. Therapeutic advances in amyotrophic lateral sclerosis. Trends Pharmacol. Sci. 18:1997;196-203.
50. Markland S. L., Westman N. G., Lundgren E., Roos G. Copper- and zinc-containing superoxide dismutase, manganese-containing superoxide dismutase, catalase, and glutathione peroxidase in normal and neoplastic human cell lines and normal human tissues. Cancer Res. 42:1982;1955-1961.
51. Martin D., Thompson M. A., Nadler J. V. The neuroprotective agent riluzole inhibits release of glutamate and aspartate from slices of hippocampal area CA1. Eur. J. Pharmacol. 250:1993;473-476.
52. Marx J. Mouse model found for ALS. Science. 264:1994;1663-1664.
53. Mena M. A., Khan U., Togasaki D. M. Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J. Neurochem. 69:1997;21-33.
54. Miller R. G., Bensimon G., Bouchard J. P. Clinical trials of riluzole in patients with amyotrophic lateral sclerosis (ALS). Neurology. 47:1996;S86-S92.
55. Mittal C. K. Nitric oxide synthase: Involvement of oxygen radicals in conversion of l-arginine to nitric oxide. Biochem. Biophys. Res. Commun. 193:1993;126-132.
56. Mulder D. W. Clinical limits of amyotrophic lateral sclerosis. Rowland L. P. Human Motor Neuron Diseases. 1982;15-22 Raven Press, New York.
57. Mulder D. W. Familial adult motor neuron disease. Neurology. 36:1986;511-517.
58. Myers M. L., Bolli R., Lekich R. F. Enhancement of recovery of myocardial function by oxygen free-radical scavengers after reversible regional ischemia. Lab. Invest. 4:1985;915-921.
59. Olanow C. W. A radical hypothesis for neurodegeneration. Trends Neurosci. 16:1993;439-444.
60. Papaioannou V. E., Fox J. G. Efficacy of tribromoethanol anesthesia in mice. Lab. Animal Sci. 43:1993;189-192.
61. Pfister H. W., Kodel U., Dirnagl U. Effect of catalase on regional cerebral blood flow and brain edema during the early phase of experimental pneumococcal meningitis. J. Infect. Dis. 166:1992;1442-1445.
62. Poduslo J. F., Curran G. L. Increased permeability across the blood-nerve barrier of albumin glycated in vitro and in vivo from patients with diabetic polyneuropathy. Proc. Natl. Acad. Sci. USA. 89:1992;2218-2222.
63. Poduslo J. F., Curran G. L. Glycation increases the permeability of proteins across the blood nerve and blood brain barriers. Mol. Brain Res. 23:1994;157-162.
64. Poduslo J. F., Curran G. L. Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J. Neurochem. 66:1996;1599-1609.
65. Poduslo J. F., Curran G. L. Increased permeability of superoxide dismutase at the blood-nerve and blood-brain barriers with retained enzymatic activity after covalent modification with the naturally occurring polyamine, putrescine. J. Neurochem. 67:1996;734-741.
66. Poduslo J. F., Curran G. L., Berg C. T. Macromolecular permeability across the blood-nerve and blood-brain barriers. Proc. Natl. Acad. Sci. USA. 9:1994;5705-5709.
67. Poduslo J. F., Curran G. L., Gill J. S. Putrescine-modified nerve growth factor: Bioactivity, plasma pharmacokinetics, blood-brain/nerve barrier permeability, and nervous system biodistribution. J. Neurochem. 71:1998;1651-1660.
68. Przedborski S., Jackson-Lewis V., Kostic V. Superoxide dismutase activities, catalase, and glutathione peroxidase activities in copper/zinc-superoxide dismutase transgenic mice. J. Neurochem. 58:1992;1760-1767.
69. Pryzedborski S., Kostic V., Jackson-Lewis V. Transgenic mice with increased Cu/Zn-superoxide dismutase activity are resistant to N-methyl-4-phenyl-1,2,3,6-tetrahydropy-ridine-induced neurotoxicity. J. Neurosci. 12:1992;1658-1667.
70. Reinholz, M. M., J. J. Haggard, G. L. Curran, and J. F. Poduslo. 1999. Plasma pharmacokinetics, nervous system biodistribution and biostability, and spinal cord permeability at the blood-brain barrier of putrescine-modified catalase in the adult rat. Exp. Neurol.159: 191-203.
71. Ripps M. E., Huntley G. W., Hof P. R. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 92:1995;689-693.
72. Rosen D. R., Siddique T., Patterson D. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 362:1993;59-62.
73. Rothstein J. D. Excitotoxicity and neurodegeneration in amyotrophic lateral sclerosis. Clin. Neurosci. 3:1996;348-359.
74. Rothstein J. D. Excitotoxicity hypothesis. Neurology. 47:1996;S19-S26.
75. Rubbo H., Darley-Usmar V., Freeman B. A. Nitric oxide regulation of tissue free radical injury. Chem. Res. Toxicol. 9:1996;809-820.
76. Sendtner M., Thoenen H. Oxidative stress and motor neuron disease. Curr. Biol. 4:1994;1036-1039.
77. Siddique T., Nijhawan D., Hentati A. Familial amyotrophic lateral sclerosis. J. Neural Trans. 49:1997;219-233.
78. Smith P. K., Krohn R. I., Hermanson G. T. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150:1985;76-85.
79. Tu P-H., Gurney M. E., Julien J-P. Oxidative stress, mutant SOD1, and neurofilament pathology in transgenic mouse models of human motor neuron disease. Lab. Invest. 76:1997;441-456.
80. Troost D., Aten J., Morsink F., Jong J. M. B. Apoptosis in amyotrophic lateral sclerosis is not restricted to motor neurons. Bcl-2 expression is increased in unaffected post-central gyrus. Neuropathol. Appl. Neurobiol. 21:1995;498-504.
81. Truelove D., Shuaib A., Ijaz S. Superoxide dismutase, catalase, and U7851F attenuate neuronal damage in gerbils with repeated brief ischemic insults. Neurochem. Res. 19:1994;665-671.
82. Wengenack T. M., Curran G. L., Olson E. E., Poduslo J. F. Putrescine-modified catalase with preserved enzymatic activity exhibits increased permeability at the blood-nerve and blood-brain barriers. Brain Res. 767:1997;128-135.
83. Wengenack T. M., Curran G. L., Poduslo J. F. Postischemic, systemic administration of polyamine-modified superoxide dismutase reduces hippocampal CA1 neurodegeneration in rat global cerebral ischemia. Brain Res. 754:1997;46-54.
84. Wiedau-Pazos W., Goto J. J., Rabizadeh S., Gralla E. B. Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science. 271:1996;515-518.
85. White L. R., Felice K. J., Chow M. S. S. Pharmacotherapeutic options in the treatment of amyotrophic lateral sclerosis. Hospital Formulary. 33:1998;44-53.
86. Wong P. C., Pardo C. A., Borchelt D. R. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron. 14:1995;1105-1116.
87. Yang G., Chan P. H., Chen J. Human copper-zinc superoxide dismutase transgenic mice are highly resistant to reperfusion injury after focal cerebral ischemia. Stroke. 25:1994;165-170.
88. Yim M. B., Chock P. B., Stadtman E. R. Enzyme function of copper, zinc superoxide dismutase as a free radical generator. J. Biol. Chem. 268:1993;4099-4105.
89. Yim M. B., Chock P. B., Stadtman E. R. Copper, zinc superoxide dismutase catalyzes hydroxyl production from hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 87:1990;5006-5010.
90. m for hydrogen peroxide. J. Biol. Chem. 272:1997;8861-8863.
91. m for hydrogen peroxide. Proc. Natl. Acad. Sci. USA. 93:1996;5709-5714.
92. Zhong L-T., Sarafian T., Kane D. J. bcl-2 inhibits death of central neural cells induced by multiple agents. Proc. Natl. Acad. Sci. USA. 90:1993;4533-4537.